• If you are wondering whether Johnson & Johnson stock still offers value after recent moves, the key question is how its current price compares with what investors are actually paying for.
• The share price recently closed at US$228.39, with returns of 10.1% year to date and 55.3% over the past year, even though the stock has declined 4.2% in the last week and is down 0.7% over the past month.
• Recent headlines around Johnson & Johnson have focused on the business as a core healthcare giant and ongoing interest in its role within the broader pharmaceuticals and biotech space. This context helps explain why the stock has seen strong one-year and multi-year returns despite short-term pullbacks.
• Simply Wall St currently gives Johnson & Johnson a value score of 4 out of 6, which reflects where the stock screens as undervalued across several checks. This sets up a closer look at methods like DCF and multiples, and then a broader way to think about valuation beyond the numbers alone.

Approach 1: Johnson & Johnson Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what Johnson & Johnson stock could be worth by projecting its future cash flows and then discounting those back to today using a required rate of return. The idea is simple: you are comparing what you pay now with the present value of the cash the company is expected to generate for shareholders.

Johnson & Johnson currently reports last twelve month free cash flow of about US$17.0b. Based on analyst inputs for the next few years and then extrapolations, Simply Wall St projects free cash flow rising to about US$35.9b by 2030, with a two stage Free Cash Flow to Equity model used to map the path from today to that 10 year point. All these cash flows are expressed in US$ and discounted back using this model description and cash flow projections.

Putting those projections together leads to an estimated intrinsic value of about US$374.05 per share, compared with the recent share price of US$228.39. That gap implies the stock screens as 38.9% undervalued on this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Johnson & Johnson is undervalued by 38.9%. Track this in your watchlist or portfolio, or discover 45 more high quality undervalued stocks.

Approach 2: Johnson & Johnson Price vs Earnings

For a profitable company like Johnson & Johnson, the P/E ratio is a useful way to relate what you pay for the stock to the earnings it generates. It gives you a quick sense of how many dollars investors are currently willing to pay for each dollar of earnings.

What counts as a normal or fair P/E depends on what investors expect for future growth and how risky those earnings appear. Higher expected growth or lower perceived risk can support a higher P/E, while slower growth or higher risk usually point to a lower multiple.

Johnson & Johnson currently trades on a P/E of 26.13x. This is very close to the peer average of 26.15x and above the broader Pharmaceuticals industry average of 14.85x. Simply Wall St also calculates a Fair Ratio of 26.45x for Johnson & Johnson. This Fair Ratio is a proprietary estimate of the P/E that might be reasonable given the company’s earnings growth profile, industry, profit margins, market cap and specific risks. This makes it more tailored than a simple comparison with peers or the sector.

With a current P/E of 26.13x versus a Fair Ratio of 26.45x, Johnson & Johnson looks ABOUT RIGHT on this metric.

Result: ABOUT RIGHT

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Johnson & Johnson Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Meet Narratives, a simple Johnson & Johnson tool on Simply Wall St’s Community page that lets you connect your story about the company to a set of revenue, earnings and margin forecasts. This then produces a Fair Value you can compare with today’s price, updates automatically when new news or earnings arrive, and can differ widely between investors. For example, one Johnson & Johnson Narrative may anchor around a Fair Value of about US$148.64 and another around US$265.00.

For Johnson & Johnson however, we’ll make it really easy for you with previews of two leading Johnson & Johnson Narratives:

First up is a bullish view that leans into the breadth of the pipeline and the scale of existing products, and compares that against where the stock trades today.

Fair value used in this bullish Johnson & Johnson Narrative: US$265.00

Implied discount to this fair value based on the last close of US$228.39: about 13.8% undervalued

Revenue growth assumption in this Narrative: 7.10% a year

• This view assumes Johnson & Johnson can build on 28 product platforms already generating at least US$1b each, with oncology, immunology, neuroscience, cardiovascular, surgery and vision all contributing to future revenue.
• Bullish analysts in this Narrative expect revenue and earnings to track toward US$115.7b of revenue and US$26.2b of earnings by 2029, with profit margins easing but still leaving room for sizeable absolute earnings.
• To reach the US$265.00 fair value, this view relies on the stock trading on a P/E of 29.9x in 2029 and discounts those cash flows back at about 7.0%, while acknowledging risks around patent expiries, pricing pressure, investment needs, acquisitions and litigation.

The second preview comes from a more cautious Johnson & Johnson Narrative that leans on blended DCF, dividend and yield based fair values.

Fair value used in this cautious Johnson & Johnson Narrative: US$148.64

Implied premium to this fair value based on the last close of US$228.39: about 53.7% overvalued

Revenue growth assumption in this Narrative: 4.73% a year

• This view anchors on modest long term revenue and free cash flow growth converging toward about 4.35%, with operating margins gradually moving toward 28% and return on invested capital settling around 15%.
• It blends three approaches, with a DCF fair value of US$146.57, a dividend discount model fair value of US$126.24 and a historical dividend yield fair value of US$187.43, with heavier weight on the cash flow and dividend models.
• It concludes that at current pricing Johnson & Johnson screens above this blended fair value, while still highlighting the company’s diversified healthcare exposure, long dividend history and role as a potential income stock.

If you want to go deeper than these snapshots and see the full reasoning, supporting charts and risk sections behind each view, you can step through the complete Narratives directly on Simply Wall St’s Community page for Johnson & Johnson, compare them with your own assumptions, and decide which story lines up better with how you see the stock.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Johnson & Johnson on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Johnson & Johnson? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.